Refine by MP, party, committee, province, or result type.

Results 1-15 of 222
Sorted by relevance | Sort by date: newest first / oldest first

International Trade committee  That is true. The Europeans were pushing for a five-year extension, which would have been a 25-year patent. The CETA negotiators managed to mitigate that, to reduce it to a two-year extension. That's what the bill says, and we believe it should be no longer than that. As for the

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  That's correct.

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  Well, that's just maintaining what we can already do, because right now, after 20-year patents expire, we can manufacture, so we can export. This means that during that two-year period, we can manufacture for export.

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  That's a very good question. That is a really critical aspect of what we're hoping will happen as a result of CETA. That, as I mentioned earlier, is going to occur with regulatory changes that come under this patent-medicine notice-of-compliance regime. These regulations are incr

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  As I said, the most important aspect is that this be applied prospectively so that the impact will be down the road eight or ten years. The clear impact is that the low-cost generics are going to be delayed two years—that's what the legislation calls for—beyond what they are now,

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  With respect to retroactivity, the provisions of Bill C-30 should apply, in terms of this patent extension or certificates of supplementary protection, only to products approved after the coming into force of CETA. The amendment we have makes that absolutely clear, and I'm hoping

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  As I said, we're going to be delayed coming to market. The good thing about this is that there was an export clause negotiated as part of CETA. It is in the bill. That mitigates some of the impact. If that is done properly, we're going to continue to push very hard to get investm

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  Generic drug manufacturers are the primary manufacturers in the pharmaceutical industry. As I said, more than 11,000 people develop and manufacture products in Canada and export them to over 100 countries. With a 12-year extension of the patent, the challenges will be greater th

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  There are two aspects to that. From a cost perspective, as I've said, generics on average now are selling at something like 20% to 25% of the price of an equivalent brand-name product. If you delay for two years, you're paying an extra 75% to 80% on that product for an extra two

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  We're asked that question regularly. The answer depends critically on how the bill is implemented, and that's one of the changes we're proposing. The changes should only apply on a prospective, go-forward basis, which means that extra patent protections should only be given to ne

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  That is correct, and it is one of the proposed amendments we have suggested. Make it crystal clear that the implementation is only to be on a go-forward basis. If you take a $100 million drug—and there are many, many of those in the Canadian market—and you delay a generic compe

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  No. The changes we're proposing are all consistent with CETA. It's just the way the changes are being interpreted in the Patent Act. As I said, 30 pages of this bill are about the Patent Act. We have gone through it very carefully and have noted that in some cases changes are no

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  That's what we would like.

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  We shared those with the clerk just yesterday.

November 29th, 2016Committee meeting

Jim Keon

International Trade committee  Thank you very much. It's nice to be back here. We were here not too long ago talking about the TPP agreement as well, which also affects pharmaceuticals. The generic pharmaceutical companies in Canada, our industry, are primarily pharmaceutical manufacturers and exporters, an

November 29th, 2016Committee meeting

Jim Keon